Edward Lifesciences Down 9% Despite Q4 Beat

Edwards Lifesciences Corp ES shares are trading lower by $9.00 at $89.02 in Thursday's session.

Despite a Q4 EPS beat of $0.03 along with a revenue beat of $8.46 million, the issue is deep in the red. This could be the result of a downgrade by BTIG, who lowered their rating on the issue from Buy To Neutral.

Its much lower opening print of $92.16 has turned out to be only $0.03 from the high of the session at $92.19. The followthrough on the downside took the issue to $86.55, but rebounded back to the mid $89.00 handle before tailing off once again. That marks the lowest level for the issue since it bottomed on December 8 at $85.27.

The issue is attempting to avoid its first close under $90.00 since December 14, when it ended that session at $89.82.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: TechnicalsIntraday UpdateMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!